| Zacks Company Profile for Pliant Therapeutics, Inc. (PLRX : NSDQ) |
|
|
| |
| • Company Description |
| Pliant Therapeutics Inc. is a late-stage biopharmaceutical company which involved in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. The company's lead product candidate includes bexotegrast. Pliant Therapeutics Inc., formerly known as PLANT THERAPEUT, is based in SOUTH SAN FRANCISCO, Calif.
Number of Employees: 171 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.40 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,590,584 shares |
| Shares Outstanding: 61.39 (millions) |
| Market Capitalization: $85.94 (millions) |
| Beta: 1.30 |
| 52 Week High: $16.10 |
| 52 Week Low: $1.10 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-4.76% |
-8.33% |
| 12 Week |
-4.11% |
-19.34% |
| Year To Date |
-89.37% |
-90.04% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
331 OYSTER POINT BLVD.
-
SOUTH SAN FRANCISCO,CA 94080
USA |
ph: 650-481-6770
fax: - |
ir@pliantrx.com |
http://pliantrx.com |
|
|
| |
| • General Corporate Information |
Officers
Bernard Coulie - Chief Executive Officer and President
Hoyoung Huh - Chairman
Keith Cummings - Chief Financial Officer
Suzanne Bruhn - Director
Darren Cline - Director
|
|
Peer Information
Pliant Therapeutics, Inc. (CORR.)
Pliant Therapeutics, Inc. (RSPI)
Pliant Therapeutics, Inc. (CGXP)
Pliant Therapeutics, Inc. (BGEN)
Pliant Therapeutics, Inc. (GTBP)
Pliant Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 729139105
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
|
|
Share - Related Items
Shares Outstanding: 61.39
Most Recent Split Date: (:1)
Beta: 1.30
Market Capitalization: $85.94 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.49 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.34 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/06/25 |
|
|
|
| |
